Genzyme General News

Dr. David Meeker, president and CEO of Cambridge, Mass.-based biotechnology company Genzyme Corp., a Sanofi company; Dr.

Sanofi's fourth quarter income of Genzyme and emerging markets offsets the death of patents and the effect of European Union rigor.

In order to facilitate an understanding of our operational performance, we comment on our business net income statement.

Genzyme , a Sanofi company , announced today four-year follow-up data from patients enrolled in the phase 2 clinical trial for its investigational oral therapy for Gaucher disease type 1 known as eliglustat tartrate.

PARIS & NEW YORK-- --Feb 8, 2012 - Sanofi and Bristol-Myers Squibb Company announced today that Apotex has made payment in the amount of $442,209,362 to Sanofi and Bristol-Myers Squibb to satisfy the damages ruling of the Plavix patent infringement case against Apotex.

Sanofi, France's biggest drugmaker, said profit may drop as much as 15 percent this year, hurt by generic competition to its Plavix blood-thinner and Avapro hypertension drug in the U.S. Earnings per share excluding some costs will probably decline between 12 percent and 15 percent at constant exchange rates, Paris-based Sanofi said in an e-mailed ... (more)

Drugmaker Sanofi SA says its earnings rose in the fourth quarter thanks to its acquisition of U.S. biotechnology firm Genzyme as well as double-digit growth in its consumer healthcare, diabetes and emerging markets businesses.

Michael Wyzga was CFO of Genzyme during its acquisition by Sanofi last April. He is now CEO of Radius Health, a Cambridge biotech seeking an IPO that focuses on osteoporosis and women's health.

The company develops and applies technologies to encounter unmet deadly diseases.

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia Genzyme Corp.'s research and development operations in Massachusetts have been cut by an unspecified number of positions, according to parent company Sanofi .

Sanofi, the new owner of Cambridge research company Genzyme, which has major manufacturing operations in Framingham, today announced plans to lay off some of its employees.

Genzyme Corp.'s research and development operations in Massachusetts have been cut by an unspecified number of positions, according to parent company Sanofi .

Correspondence : Belinda R. Lennox, DM, MRCPsych, Department of Psychiatry, University of Cambridge, Herchel Smith Building, Cambridge Biomedical Campus, Addenbrooke's Hospital, Cambridge CB2 2QQ, UK.

Wills Hughes-Wilson has been appointed Vice President, Government Affairs & Policy with responsibility for Sobi's contacts with all stakeholders in the health policy area.

Suburban Propane Partners LP : Jim Cramer ranked this stock a Sell . The stock closed at $45.13, its 52-week high is $58.49, and its 52-week low is $40.25. Sanofi-Aventis : Jim Cramer ranked this stock a Buy .

Amgen and Micromet announced that the companies have entered into a definitive merger agreement under which Amgen will acquire Micromet, a biotechnology company founded in Germany with its research and development center in Munich and headquarters in Rockville, Md., for $11 per share in cash.

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia By Michelle Wong, BioSpace.com Massachusetts is picking up steam in the biotech industry while other states have been struggling to stay afloat in this tough economy.

Sanofi Chief Executive Officer Chris Viehbacher sees "a few signs" pointing to a recovery in Europe although it's too soon to tell whether the region's debt crisis may be approaching an end.

French drug-maker Sanofi, which acquired Genzyme Corp, has announced that the Food and Drug Administrator has given approval to its new plant to manufacture Fabrazyme, a drug used for the treatment of Fabry disease.

Below are company-related news and stories from French and Benelux media which could have an impact on the region's markets or individual stocks.